logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor class drugs

    FiltersReset Filters
    8 results

    • apretude

      (Cabotegravir)
      ViiV Healthcare Company
      Usage: APRETUDE is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk of HIV-1. A negative HIV-1 test is required before starting treatment.

    • cabenuva

      (cabotegravir and rilpivirine)
      ViiV Healthcare Company
      Usage: CABENUVA is indicated as a complete regimen for treating HIV-1 infection in adults and adolescents aged 12 and older (weighing at least 35 kg) who are virologically suppressed and stable on their current antiretroviral therapy, with no treatment failure history or known resistance to its components.

    • dovato

      (dolutegravir sodium and lamivudine)
      ViiV Healthcare Company
      Usage: DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (12 years and older, weighing at least 25 kg) who are either treatment-naive or virologically suppressed on a stable regimen without known resistance issues.

    • genvoya

      (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
      Gilead Sciences, Inc.
      Usage: GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.

    • isentress

      (RALTEGRAVIR)
      Merck Sharp & Dohme LLC
      Usage: ISENTRESS® and ISENTRESS® HD are indicated for the treatment of HIV-1 infection in adults and pediatric patients, used in combination with other antiretroviral agents. ISENTRESS is for children weighing at least 2 kg, while ISENTRESS HD is for those weighing at least 40 kg.

    • juluca

      (dolutegravir sodium and rilpivirine hydrochloride)
      ViiV Healthcare Company
      Usage: JULUCA is indicated for treating HIV-1 infection in virologically suppressed adults, replacing their current antiretroviral regimen. Eligible patients must have maintained suppression for at least 6 months, have no treatment failures, and no known resistance to JULUCA's components.

    • stribild

      (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
      Gilead Sciences, Inc.
      Usage: STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.

    • triumeq

      (abacavir sulfate, dolutegravir sodium, lamivudine)
      ViiV Healthcare Company
      Usage: TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing at least 6 kg. They are not recommended for patients with integrase resistance or suspected INSTI resistance due to insufficient dolutegravir dosage.